news

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

1
SHARES

Privately-owned Grünenthal estimates the Nebido brand will add about €100 million to its EBITDA in 2023.

Grünenthal

Grünenthal has agreed to acquire testosterone treatment NebidoTM and its associated brands from Bayer AG, for up to €500 million.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The long-acting injectable treatment for testosterone deficiency has been commercially approved in more than 80 countries. Nebido is also patented until March 2024 in the European Union and until May 2027 in the United States.

Nebido is typically administered by a physician every 10-14 weeks for treatment of male hypogonadism or testosterone deficiency,

It can also be used to treat clinical symptoms such as regression of secondary sexual characteristics, change in body composition, asthenia, reduced libido or erectile dysfunction.

“One in six men over 50 live with the symptoms of testosterone deficiency. Too few of these patients receive appropriate treatment. We are committed to facilitating access to treatment for even more patients in need,” commented Gabriel Baertschi, CEO of Grünenthal.

The deal is expected to close by the end of 2022, subject to approval by the relevant competition authorities.

Grünenthal has invested over €2 billion in successful M&A transactions over the last several years. The latest deal to buy testosterone treatment Nebido from Bayer will expand its existing portfolio of medicines. 

In 2018, Grünenthal acquired the European rights to Nexium™ as well as the global rights to Vimovo™ (ex-US and Japan) from AstraZeneca. Nexium helps to reduce the amount of acid produced by the stomach in patients with gastrointestinal reflux conditions and ulcers. Vimovo is a modified-release fixed-dose combination tablet of naproxen, a pain-relieving NSAID and esomeprazole, the active ingredient in Nexium, for the treatment of various inflammatory diseases.

Grünenthal also acquired the European rights (excluding Spain and the UK) to statin CRESTOR™  from AstraZeneca, the rights to Qutenza™ (capsaicin 8% patch) from Astellas Pharma Europe, and has the global rights (excluding Japan) to AstraZeneca’s migraine therapy Zomig™.

In 2021, Grünenthal acquired Mestex AG, a Swiss biotech, and its clinical phase medicine resiniferatoxin (MTX-071) for the intra-articular treatment of pain associated with osteoarthritis of the knee.

Related topics

,

Related organisations

,

Related people

Related diseases & conditions

,

Share via
Share via